High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer-Reference-Cited by-同舟云学术

High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer

Published:2018-08 Issue:6 Volume:16 Page:297-319
ISSN:1540-658X
Container-title:ASSAY and Drug Development Technologies
language:en
Short-container-title:ASSAY and Drug Development Technologies

Author:

Fancher Ashley T.¹,Hua Yun¹,Camarco Daniel P.¹,Close David A.¹,Strock Christopher J.²,Johnston Paul A.¹³

Affiliation:

1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.

2. Apredica, Cyprotex US, Watertown, Massachusetts.

3. University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/adt.2018.858

Reference58 articles.

1. Cancer statistics, 2013

2. Characterising the castration-resistant prostate cancer population: a systematic review

3. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation–Drug leads for metastatic castration resistant prostate cancer;SLAS Discovery;2023-10

2. Current and emerging approaches to noncompetitive AR inhibition;Medicinal Research Reviews;2023-04-16

3. Selecting a minimal set of androgen receptor assays for screening chemicals;Regulatory Toxicology and Pharmacology;2020-11

4. Chemical Screening of Nuclear Receptor Modulators;International Journal of Molecular Sciences;2020-07-31

5. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor;ASSAY and Drug Development Technologies;2019-12-01